Henlius (pertuzumab biosimilar) for treating HER2-positive breast cancer [TS ID 12094]

Status:

Topic prioritisation

Technology type:

Medicine

Decision:

Not selected

Reason for decision:

Not eligible for Health Technology Evaluation guidance

Rationale:

Decision makers have concluded that the clear rationale to not evaluate your product is due to your product being a biosimilar of published TA509. Generic or biosimilar medicines are not considered by NICE if the branded version is recommended in NICE technology appraisal or highly specialised technologies guidance. Please see 3 Topics that are not usually considered by NICE | NICE-wide topic prioritisation: the manual | Guidance | NICE for further information.

ID number:

12094

Project Team

Project lead

Danielle Lees

Email enquiries

If you have any queries please email topic.selection@nice.org.uk

Timeline

Key events during the development of the guidance:

For further information on how we select topics for development, please see our page about topic prioritisation